Warren Buffett Thinks Investors Are "Gambling" Right Now. Here are 2 Stocks That Should Be Safe Bets.

The article highlights dividend growth and resilient demand for defensives: Merck raised its quarterly dividend 5% to $0.85 (26th consecutive increase; 2.48% yield) and Johnson & Johnson raised its dividend 3% (64th consecutive; 1.94% yield). It cites operating momentum with Merck Q2 sales of $16.6B (+5% YoY) and Johnson & Johnson Q2 revenue of $25.3B (+6.6% YoY). Both companies are framed as long-duration healthcare cash-flow compounders supported by heavy R&D ($9.7B at Merck in Q2; $7.1B at J&J over six months) and recent FDA approvals, with shares up ~28% (Merck) and ~30% (J&J) in 2026 YTD.

Analysis

The real market mechanism here is not “defensive stocks go up in a bubble,” it’s that capital is migrating toward cash-flow visibility while investors debate duration risk. That favors JNJ more than MRK: JNJ’s mix is broader, so it has less single-product earnings cliff risk and more ability to convert incremental procedure volumes into durable margin expansion. The second-order winner from JNJ’s robotics push is likely the hospital-capex ecosystem and service/software attach, while the more obvious loser is incumbent surgical robotics leadership (ISRG) if JNJ can price systems aggressively and bundle consumables.

MRK is better viewed as a late-cycle cash machine with embedded option value, not a clean secular compounder. The key question is whether pipeline wins can outrun the eventual multiple compression that typically shows up 6-18 months before a major franchise matures; if not, the stock can look “cheap” right up until growth slows. MRNA gets some read-through from oncology vaccine validation, but the financial impact is still years away and should be treated as platform optionality rather than a near-term revenue bridge.

Contrarian take: the defensive trade may be crowded. If recession odds fall or the market re-prices growth higher on easier rates, JNJ/MRK can underperform on relative multiple, even if fundamentals stay fine. The falsifier for the bull case is not macro weakness; it’s slower-than-expected procedure growth for JNJ or any sign that MRK’s core oncology growth falls to low-single digits faster than consensus models expect.

Key Decisions for Investors

• Long JNJ / short XBI on a 3-6 month horizon: express quality-over-speculation and defensive cash-flow preference; risk/reward improves if biotech sentiment remains rate-sensitive and risk appetite cools.
• Relative value: long JNJ / short MRK into strength if the market starts pricing the Keytruda cliff earlier than management’s mitigation plan; thesis breaks if MRK shows sustained mid-single-digit core growth ex-Keytruda.
• Buy JNJ on pullbacks after any post-article strength fade; the cleaner catalyst path is medtech adoption and capital return, but only if procedure volumes keep compounding over the next 2-3 quarters.
• Watch-only alert on MRNA: if oncology vaccine data translates into a partnership or phase-3-driven revenue forecast upgrade, it becomes a multi-year optionality trade; otherwise do not chase on headline validation alone.
• If 10Y yields re-accelerate and growth leadership returns, cut defensive longs first — that macro shift would likely compress JNJ/MRK relative outperformance within days to weeks.